OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance
Haozhe Zhang, Zhou Yi, Zengzhen Xing, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 13521-13521
Open Access | Times Cited: 22

Showing 22 citing articles:

Therapeutic potential and limitations of curcumin as antimetastatic agent
Petr Dytrych, Zdeněk Kejík, Jan Hajduch, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 163, pp. 114758-114758
Open Access | Times Cited: 26

Gut microbiome: a novel preventive and therapeutic target for prostatic disease
Hongliang Cao, Difei Zhang, Pengyu Wang, et al.
Frontiers in Cellular and Infection Microbiology (2024) Vol. 14
Open Access | Times Cited: 5

Cytotoxicity, antiprostate cancer effects, and phytochemical composition of the dichloromethane stem bark extract of Acacia gerrardii (Benth.)
Gervason Moriasi, Mathew Piero Ngugi, Peter Mwitari, et al.
Next research. (2025), pp. 100167-100167
Closed Access

Unveiling the latest insights into Androgen Receptors in Prostate Cancer
Suleiman Zakari
International journal of medical biochemistry/International journal of medical biochemistry : (2024), pp. 101-113
Open Access | Times Cited: 3

Assessing the Potential of Small Peptides for Altering Expression Levels of the Iron-Regulatory Genes FTH1 and TFRC and Enhancing Androgen Receptor Inhibitor Activity in In Vitro Prostate Cancer Models
Crawford Currie, Christian Bjerknes, Tor Åge Myklebust, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15231-15231
Open Access | Times Cited: 5

Periprostatic Adipose Tissue: A New Perspective for Diagnosing and Treating Prostate Cancer
Hongliang Cao, Yishu Wang, Difei Zhang, et al.
Journal of Cancer (2023) Vol. 15, Iss. 1, pp. 204-217
Open Access | Times Cited: 5

The influence of sex hormones on renal cell carcinoma
Michael Ladurner, Andrea Katharina Lindner, Peter Rehder, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 1

Preliminary efficacy, tolerability, and safety analysis of Darolutamide for metastatic castration‑resistant prostate cancer: a single-center, open-label study
Junjie Yu, Kaichen Zhou, J. Wang, et al.
Urologia Internationalis (2024), pp. 1-8
Closed Access | Times Cited: 1

Research progress on FSH-FSHR signaling in the pathogenesis of non-reproductive diseases
Chenhe Li, Ling Yan, Haibin Kuang
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 1

Human Cytochrome P450 Cancer-Related Metabolic Activities and Gene Polymorphisms: A Review
Innokenty M. Mokhosoev, Dmitry V. Astakhov, Alexander A. Terentiev, et al.
Cells (2024) Vol. 13, Iss. 23, pp. 1958-1958
Open Access | Times Cited: 1

Recent advances in anticancer peptoids
Jidan Zhu, Siyu Chen, Ziwei Liu, et al.
Bioorganic Chemistry (2023) Vol. 139, pp. 106686-106686
Closed Access | Times Cited: 3

Discovery of Potent, Selective, and Orally Bioavailable DYRK2 Inhibitors for the Treatment of Prostate Cancer
Kai Yuan, Fei Xia, Qiannan Li, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 23, pp. 16235-16256
Closed Access | Times Cited: 3

Unlocking the Secrets of Androgen Receptors in the Susceptibility, Progression, and Treatment of Prostate Cancer
Suleiman Zakari, Christogonus C. Ekenwaneze, Emmanuel Amadi, et al.
(2023)
Open Access | Times Cited: 2

Unlocking the Secrets of Androgen Receptors in the Susceptibility, Progression, and Treatment of Prostate Cancer
Suleiman Zakari, Christogonus C. Ekenwaneze, Emmanuel Amadi, et al.
(2023)
Open Access | Times Cited: 2

Role of Circadian Rhythm in Hormonal Cancers
Divya Jyoti, Shivani Guleria, Aitizaz Ul Ahsan, et al.
(2024), pp. 509-535
Closed Access

Association Between Major Adverse Cardiac Events and Hormone Therapy Usage in Prostate Cancer Patients of a Diverse Cohort
Yuanchu J Yang, Chenjie Zeng, Kerry Schaffer, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access

Altered amino and fatty acids metabolism in Sudanese prostate cancer patients: insights from metabolic analysis
Dalia Ahmed, Ebtesam A. Abdel-Shafy, E. Mohammed, et al.
Journal of Circulating Biomarkers (2024) Vol. 13, Iss. 1, pp. 36-44
Open Access

The effect of the discrepancy between pre- and post-operative staging on decision-making and quality of life in men undergoing a radical prostatectomy
Álvaro Martínez-Bordajandi, Ana Patricia Puga-Mendoza, Gonzalo Granero‐Heredia, et al.
Journal of Men s Health (2023)
Open Access

THE ROLE OF THE ANDROGEN RECEPTOR IN PROSTATE CANCER
Anna Barnaś, Andrzej Antczak, Wojciech A. Cieślikowski
Postępy Biologii Komórki (2023) Vol. 50, Iss. 1, pp. 19-26
Open Access

Page 1

Scroll to top